Last edition
News about "Narcolepsy"
Lundbeck's Oral Narcolepsy Drug Candidate Receives FDA Fast Track Designation
Lundbeck has received FDA Fast Track designation for Lu AH69593, its investigational oral orexin 2 receptor agonist, accelerating the development of a potential new treatment for patients living with narcolepsy.
Narcolepsy | 27/07/2026 | By News Bureau
Lilly Completes Acquisition of Centessa to Advance Sleep Disorder Therapies
Lilly expands its neuroscience portfolio with the acquisition of Centessa Pharmaceuticals to accelerate treatments for narcolepsy and related sleep disorders.
Narcolepsy | 26/06/2026 | By News Bureau | 114
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy